November 2019- Volume 15, Issue 11

In this Issue

Business & Government Policy

Patent Docs: Sovereign immunity not absolute for states under the Eleventh Amendment

Patent Docs: Sovereign immunity not absolute for states under the Eleventh Amendment

Kevin Noonan discusses a case in which the University of Texas sued Boston Scientific for patent infringement related to implantable drug-releasing biodegradable fibers

Passing some gems to Emerald

Passing some gems to Emerald

Amarantus enters into agreement to license diverse therapeutics portfolio to CBD-focused company

On the cutting edge

On the cutting edge

A roundup of instrumentation, software and other tools and technology news

Pushing the envelope

Pushing the envelope

Duke launches center to explore innovative science and technology policy

Major option for microinjector

Major option for microinjector

Clearside announces option exercise by REGENXBIO for gene therapy delivery tech

It’s all in the delivery

It’s all in the delivery

Checking out the news in drug delivery advancements

Diagnostics

Betting on the future

Betting on the future

Illumina, QIAGEN look to stake their claim on the NGS IVD market

Advancing nuclear medicine to treat cancer

Advancing nuclear medicine to treat cancer

Fuzionaire Diagnostics partners with Japan Medical Isotope Technology Development to launch new firm

Transformative technology

Transformative technology

Mount Sinai establishes institute for research and training

Prostates and PARPs

Prostates and PARPs

Theragnostics makes moves on the prostate front

Research & Development

Untangling the knot

Untangling the knot

USC researchers publish results in Cell Stem Cell that could prove the key to effective, reproducible cell reprogramming

Stanford on the mind

Stanford on the mind

University teams make progress on rare CNS disease and identify a potential Parkinson’s biomarker

Improving the innovation lifecycle

Improving the innovation lifecycle

CAS launches Formulus in effort to help fast-track product development

Calculating the risk

Calculating the risk

Elsevier and pharma industry leaders to build new drug-drug interaction risk calculator

Discovery

Building off of nature’s basics

Building off of nature’s basics

New antibacterial tactic harnesses natural enzymes to kill bacteria

A mutual microbiome plan

A mutual microbiome plan

Kaleido Biosciences collaborates with Gustave Roussy to develop Microbiome Metabolic Therapies

Emulating diabetes for drug discovery

Emulating diabetes for drug discovery

Collaboration will develop three-dimensional models

New target for two tricky cancers

New target for two tricky cancers

Blocking a specific protein reduces fibrosis and thwarts ovarian and pancreatic cancer

Preclinical

Auransa advances AU-409

Auransa advances AU-409

Company presents new preclinical data on its potential treatment for hepatocellular carcinoma

Joining hands on first-in-class cancer therapy

Joining hands on first-in-class cancer therapy

Ivy Brain Tumor Center and Salarius conduct preclinical study to test seclidemstat

Repurposed receptor

Repurposed receptor

Drug is said to reduce pulmonary fibrosis by 56 percent

Biocon in-licenses early-stage biosimilar from Evotec

Biocon in-licenses early-stage biosimilar from Evotec

Company will undertake development, manufacturing and commercialization under its own label

Clinical Trials

Dynamic progress for diabetes

Dynamic progress for diabetes

Two companies are making large strides in the diabetes realm

Riding the waves of Lonsurf

Riding the waves of Lonsurf

Taiho Oncology reports promising findings for patients with prior gastrectomy

A new idea with IDO

A new idea with IDO

Phase 2 trial evaluates a new tool in pediatric cancer immunotherapy

Reata’s omav shows its MOXIe

Reata’s omav shows its MOXIe

Investigational treatment for Friedreich’s ataxia leads to significant improvement in patient scores

Commentary

Out of order: Not to be negative

Out of order: Not to be negative

The very fact that we define results as positive or negative highlights our reluctance to accept change, that the story we have built in our heads may not fully reflect our reality

Contract Services

Gaining ground

Gaining ground

QPS announces new clinics in three key areas for CRO market growth

They can’t ‘contain’ themselves

They can’t ‘contain’ themselves

Burgeoning oncology pipeline increases demand for containment manufacturing, which is good news for many CMOs

Global workforce challenges for CROs

Global workforce challenges for CROs

VIARES partners with ACRP to help address these issues

Editor's Focus

Editor’s Focus: Organic is often good for you

Editor’s Focus: Organic is often good for you

It seems there might be a trend away from crude and opportunistic tack-on merger and acquisition deals and toward more deliberate M&A deals that better fit companies' current and future needs, which would be welcome in an era when internal, organic R&D growth isn't what it used to be

Feature

2019 ASCB|EMBO Show Preview: A biologically dynamic duo

2019 ASCB|EMBO Show Preview: A biologically dynamic duo

Year three of the collaborative ASCB|EMBO meeting presents a wide variety of innovative cell biology research
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all the latest DDN news!

Latest Issue  

• Volume 17 • Issue 6 • June 2021

June 2021

June 2021 issue